Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/23362
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorGRANGEIRO, Alexandre-
dc.contributor.authorESCUDER, Maria Mercedes-
dc.contributor.authorMENEZES, Paulo Rossi-
dc.contributor.authorALENCAR, Rosa-
dc.contributor.authorCASTILHO, Euclides Ayres de-
dc.date.accessioned2017-11-27T16:34:05Z-
dc.date.available2017-11-27T16:34:05Z-
dc.date.issued2011-
dc.identifier.citationPLOS ONE, v.6, n.1, article ID e14585, 11p, 2011-
dc.identifier.issn1932-6203-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/23362-
dc.description.abstractBackground: Worldwide, a high proportion of HIV-infected individuals enter into HIV care late. Here, our objective was to estimate the impact that late entry into HIV care has had on AIDS mortality rates in Brazil. Methodology/Principal Findings: We analyzed data from information systems regarding HIV-infected adults who sought treatment at public health care facilities in Brazil from 2003 to 2006. We initially estimated the prevalence of late entry into HIV care, as well as the probability of death in the first 12 months, the percentage of the risk of death attributable to late entry, and the number of avoidable deaths. We subsequently adjusted the annual AIDS mortality rate by excluding such deaths. Of the 115,369 patients evaluated, 50,358 (43.6%) had entered HIV care late, and 18,002 died in the first 12 months, representing a 16.5% probability of death in the first 12 months (95% CI: 16.3-16.7). By comparing patients who entered HIV care late with those who gained timely access, we found that the risk ratio for death was 49.5 (95% CI: 45.1-54.2). The percentage of the risk of death attributable to late entry was 95.5%, translating to 17,189 potentially avoidable deaths. Averting those deaths would have lowered the 2003-2006 AIDS mortality rate by 39.5%. Including asymptomatic patients with CD4(+) T cell counts >200 and <= 350 cells/mm(3) in the group who entered HIV care late increased this proportion by 1.8%. Conclusions/Significance: In Brazil, antiretroviral drugs reduced AIDS mortality by 43%. Timely entry would reduce that rate by a similar proportion, as well as resulting in a 45.2% increase in the effectiveness of the program for HIV care. The World Health Organization recommendation that asymptomatic patients with CD4(+) T cell counts <= 350 cells/mm(3) be treated would not have a significant impact on this scenario.-
dc.description.sponsorshipBrazilian National Ministry of Health-
dc.description.sponsorshipDeutsche Gesellschaft fur Technische Zusammenarbeit (GTZ, German Agency for Technical Cooperation) in Brazil-
dc.description.sponsorshipBrazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, National Council for Scientific and Technological Development)-
dc.language.isoeng-
dc.publisherPUBLIC LIBRARY SCIENCE-
dc.relation.ispartofPlos One-
dc.rightsopenAccess-
dc.subject.otherantiretroviral therapy-
dc.subject.otherhiv-1-infected patients-
dc.subject.otherunited-states-
dc.subject.othergender-differences-
dc.subject.otherinfected patients-
dc.subject.othermedical-care-
dc.subject.othersao-paulo-
dc.subject.other1st year-
dc.subject.otherdiagnosis-
dc.subject.othersettings-
dc.titleLate Entry into HIV Care: Estimated Impact on AIDS Mortality Rates in Brazil, 2003-2006-
dc.typearticle-
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCE-
dc.identifier.doi10.1371/journal.pone.0014585-
dc.identifier.pmid21283618-
dc.subject.wosMultidisciplinary Sciences-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalESCUDER, Maria Mercedes:Secretaria Estado Saude Sao Paulo, Inst Saude, Sao Paulo, Brazil-
hcfmusp.author.externalALENCAR, Rosa:Secretaria Estado Saude Sao Paulo, Ctr Referencia & Treinamento DST Aids, Sao Paulo, Brazil-
hcfmusp.description.articlenumbere14585-
hcfmusp.description.issue1-
hcfmusp.description.volume6-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000286661400003-
hcfmusp.origem.id2-s2.0-79551537508-
hcfmusp.publisher.citySAN FRANCISCO-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceGrangeiro A, 2009, CAD SAUDE PUBLICA, V25, P2053, DOI 10.1590/S0102-311X2009000900019-
hcfmusp.relation.referenceChasombat S, 2009, JAIDS-J ACQ IMM DEF, V50, P506, DOI 10.1097/QAI.0b013e3181967602-
hcfmusp.relation.referenceEgger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4-
hcfmusp.relation.referenceLawn SD, 2009, AIDS, V23, P335, DOI 10.1097/QAD.0b013e328321823f-
hcfmusp.relation.referenceTuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a-
hcfmusp.relation.referenceBraitstein P, 2006, LANCET, V367, P817-
hcfmusp.relation.referenceThanawuth N, 2008, AIDS CARE, V20, P43, DOI 10.1080/09540120701439303-
hcfmusp.relation.referenceAttia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca-
hcfmusp.relation.referenceDeblonde J, 2010, EUR J PUBLIC HEALTH, V20, P422, DOI 10.1093/eurpub/ckp231-
hcfmusp.relation.referenceFonseca MGP, 2010, CAD SAUDE PUBLICA, V26, P1431, DOI 10.1590/S0102-311X2010000700022-
hcfmusp.relation.referenceZhang FJ, 2009, ANN INTERN MED, V151, P241-
hcfmusp.relation.referenceDelpierre C, 2007, INT J STD AIDS, V18, P312, DOI 10.1258/095646207780749709-
hcfmusp.relation.referenceBraga PE, 2007, CAD SAUDE PUBLICA, V23, P2653, DOI 10.1590/S0102-311X2007001100013-
hcfmusp.relation.referenceObermeyer CM, 2007, AM J PUBLIC HEALTH, V97, P1762, DOI 10.2105/AJPH.2006.096263-
hcfmusp.relation.referenceGranich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9-
hcfmusp.relation.referenceKrentz HB, 2004, HIV MED, V5, P93, DOI 10.1111/j.1468-1293.2004.00193.x-
hcfmusp.relation.referenceBurns FM, 2008, AIDS, V22, P115-
hcfmusp.relation.referenceOkie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069-
hcfmusp.relation.referenceBraga P, 2007, AIDS PATIENT CARE ST, V21, P321, DOI 10.1089/apc.2006.0111-
hcfmusp.relation.reference*BRAZ MIN HLTH HLT, 2008, UN GEN ASS SPEC SESS-
hcfmusp.relation.referenceBrinkhof MWG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000066-
hcfmusp.relation.referenceCampos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c-
hcfmusp.relation.referenceCARNICERPONT D, 2006, CURRENT HIV RES, V7, P237-
hcfmusp.relation.referenceShouse R. L., 2009, Morbidity and Mortality Weekly Report, V58, P661-
hcfmusp.relation.referenceDONNELL D, 2010, LANCET, DOI 10.1016/SO140-6736(10)60705-2-
hcfmusp.relation.referenceFernandes JRM, 2009, CAD SAUDE PUBLICA, V25, P1369, DOI 10.1590/S0102-311X2009000600019-
hcfmusp.relation.referenceFonseca MGP, 2007, CAD SAUDE PUBLICA, V23, pS333, DOI 10.1590/S0102-311X2007001500002-
hcfmusp.relation.referenceFranca I, 2008, REV SAUDE PUBL, V42-
hcfmusp.relation.referenceFUENTE L, 2009, J EPIDEMIOL COMMUNIT, V63, P552-
hcfmusp.relation.referenceGonçalves Valéria Freire, 2008, Rev. bras. epidemiol., V11, P356, DOI 10.1590/S1415-790X2008000300003-
hcfmusp.relation.referenceKeiser O, 2008, TROP MED INT HEALTH, V13, P870, DOI 10.1111/j.1365-3156.2008.02078.x-
hcfmusp.relation.referenceKelsey JL, 1996, METHODS OBSERVATIONA-
hcfmusp.relation.referenceLemos KRV, 2001, CAD SAUDE PUBLICA, V17, P617-
hcfmusp.relation.referenceLucena FFA, 2006, CADERNOS SAUDE COLET, V14, P305-
hcfmusp.relation.referenceJorge Maria Helena Prado de Mello, 2007, Cien Saude Colet, V12, P643, DOI 10.1590/S1413-81232007000300014-
hcfmusp.relation.reference*MIN SAUD BRAS, 2000, REC TER ANT AD AD IN-
hcfmusp.relation.referenceOstermann J, 2007, ARCH INTERN MED, V167, P2128, DOI 10.1001/archinte.167.19.2128-
hcfmusp.relation.referencePaltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088-
hcfmusp.relation.referenceReed JB, 2009, AIDS PATIENT CARE ST, V23, P765, DOI 10.1089/apc.2008.0213-
hcfmusp.relation.referenceSevere P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370-
hcfmusp.relation.referenceSiegfried N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008272.pub2-
hcfmusp.relation.referenceSIGHEN V, 2005, J ACQ IMMUN DEF SYND, V40, P212-
hcfmusp.relation.referenceSignorelli C, 2006, EUR J PUBLIC HEALTH, V16, P498, DOI 10.1093/eurpub/ckl024-
hcfmusp.relation.reference*SMART STUD GROUP, 2008, J INFECT DIS, V197, P1133-
hcfmusp.relation.referenceSouza PRB, 2007, CLINICS, V62, P579, DOI 10.1590/S1807-59322007000500008-
hcfmusp.relation.referenceWHO, 2009, RAP ADV ANT THER HIV-
hcfmusp.relation.referenceWorld Health Organization Joint United Nations Programme on HIV/AIDS and UNICEF, 2009, UN ACC SCAL PRIOR HI-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus50-
hcfmusp.scopus.lastupdate2024-04-18-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPR
Departamento de Medicina Preventiva - FM/MPR

Artigos e Materiais de Revistas Científicas - LIM/39
LIM/39 - Laboratório de Processamento de Dados Biomédicos


Files in This Item:
File Description SizeFormat 
art_GRANGEIRO_Late_Entry_into_HIV_Care_Estimated_Impact_on_2011.PDFpublishedVersion (English)385.91 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.